Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

145.24USD
1:30am IST
Change (% chg)

$0.16 (+0.11%)
Prev Close
$145.08
Open
$145.74
Day's High
$147.47
Day's Low
$144.35
Volume
1,098,788
Avg. Vol
1,997,470
52-wk High
$157.00
52-wk Low
$109.17

Select another date:
Photo

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

WRAPUP 7-AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

Oct 23 AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday.

J&J preparing to resume U.S. trial of COVID-19 vaccine candidate

Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.

J&J preparing to resume U.S. trial of COVID-19 vaccine candidate

Oct 23 - Johnson & Johnson said on Friday it was preparing to resume a large clinical trial of its experimental COVID-19 vaccine in the United States after an independent safety panel recommended enrollments for the study.

Johnson & Johnson coronavirus vaccine trial to resume soon: Washington Post

Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter.

Johnson & Johnson coronavirus vaccine trial to resume soon - Washington Post

Oct 23 Johnson & Johnson's coronavirus vaccine trial will resume very soon after investigators concluded a participant's illness was unrelated to the vaccine, the Washington Post reported on Friday, citing two people familiar with the matter. (Reporting by Munsif Vengattil; Editing by Anil D'Silva)

BRIEF-Johnson & Johnson coronavirus vaccine trial will resume soon - Washington Post

* JOHNSON & JOHNSON CORONAVIRUS VACCINE TRIAL, PAUSED DUE TO AN UNEXPLAINED ILLNESS IN A PARTICIPANT, WILL RESUME VERY SOON - WASHINGTON POST Source: https://wapo.st/2HsTJwc Further company coverage:

BRIEF-Operation Warp Speed Chief Slaoui Expects U.S. Trials Of Vaccines Made By Astrazeneca And Johnson & Johnson To Resume As Soon As This Week-Bloomberg

* OPERATION WARP SPEED CHIEF SLAOUI EXPECTS U.S. TRIALS OF VACCINES MADE BY ASTRAZENECA AND JOHNSON & JOHNSON TO RESUME AS SOON AS THIS WEEK-BLOOMBERG Source text : https://bloom.bg/3dOr9RT Further company coverage:

EU signs supply deal with J&J on potential COVID-19 vaccine

BRUSSELS The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.

EU signs supply deal with J&J on potential COVID-19 vaccine

BRUSSELS, Oct 21 The European Commission said on Wednesday it had signed a contract on behalf of EU states with U.S. drugmaker Johnson & Johnson for the supply of 400 million doses of its COVID-19 vaccine candidate.

Select another date: